Article Details
Retrieved on: 2018-02-03 18:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Cambridge startup Intellegens has secured a landmark maiden deal for its Alchemite™ <b>artificial intelligence</b> technology. The company has revealed its first commercial collaboration – with e-Therapeutics, an Oxford-based pioneer of Network-Driven Drug Discovery. Alchemite will enable e-Therapeutics ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here